Assertio Extends Garda Acquisition Deadline to May 4
Event summary
- Assertio and Garda mutually agreed to extend the tender offer deadline for Assertio's acquisition to May 4, 2026.
- Garda's original offer was $18.00 per share in cash ($125.1 million total) plus a contingent value right.
- The deal includes a 20-day 'window-shop' period allowing Assertio to seek superior bids with reduced breakup fees.
- Assertio focuses on commercializing oncology products.
The big picture
This extension reflects typical M&A due diligence timelines but also signals potential competitive interest. The $125.1 million deal size positions Assertio as a mid-tier acquisition in the oncology commercialization space, where consolidation trends continue amid rising R&D costs and market access challenges.
What we're watching
- Competing Bids
- Whether Assertio receives superior offers during the window-shop period that could alter the transaction.
- Regulatory Approval
- The pace at which regulatory approvals progress and potential hurdles in closing the deal.
- Contingent Value Risk
- How the contingent value right impacts shareholder returns if milestones are not achieved.
Related topics